Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LAP3 | P28838 | 3/20 | 0.39 |
| ▸ | MMP1 | P03956 | 2/20 | 0.37 |
| ▸ | MMP2 | P08253 | 2/20 | 0.37 |
| ▸ | METAP1 | P53582 | 1/20 | 0.37 |
| ▸ | MMP3 | P08254 | 1/20 | 0.37 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.34 |
| ▸ | FDPS | P14324 | 4/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ANPEP | P15144 | 4/20 | 0.31 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2185946 | 0.97 | LAP3 (0.37) | LAP3MMP1MMP2METAP1MMP3 | |
| SCHEMBL11410937 | 0.93 | CTSA (0.37) | LAP3MMP1MMP2METAP1MMP3 | |
| SCHEMBL6014564 | 0.89 | LAP3 (0.41) | LAP3METAP1FDPSANPEPERAP1 | |
| SCHEMBL13557334 | 0.88 | MMP1 (0.38) | LAP3MMP1MMP2METAP1MMP3 | |
| SCHEMBL11409309 | 0.86 | PPARD (0.39) | LAP3MMP1MMP2METAP1MMP3 | |
| SCHEMBL2863833 | 0.86 | BTN3A1 (0.38) | LAP3METAP1SMPD1FDPS | |
| SCHEMBL485995 | 0.84 | — | — | |
| SCHEMBL13147013 | 0.83 | LAP3 (0.31) | LAP3MMP1MMP2METAP1MMP3 | |
| SCHEMBL6136707 | 0.83 | LAP3 (0.31) | LAP3MMP1MMP2METAP1MMP3 | |
| Hydrochloric Acid SCHEMBL6047705 | 0.82 | SMPD1 (0.42) | LAP3MMP1MMP2METAP1MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12296304-B2 | Membrane for water filtration | AQUAPORIN A/S (DK) | 2025-05-13 | — | — | US | disclosed |
| EP-4277731-B1 | PROCESS FOR PREPARING A MEMBRANE | AQUAPORIN AS (DK) | 2024-10-09 | — | — | EP | disclosed |
| US-20240058768-A1 | MEMBRANE FOR WATER FILTRATION | AQUAPORIN A/S (DK) | 2024-02-22 | — | — | US | disclosed |
| EP-4277731-A1 | MEMBRANE FOR WATER FILTRATION | Aquaporin A/S (DK) | 2023-11-22 | — | — | EP | disclosed |
| WO-2023219658-A2 | MULTI-LAYERED COATED METAL SUBSTRATES | PRC-DESOTO INTERNATIONAL, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| CN-116745025-A | membrane for water filtration | 水通道蛋白有限公司 | 2023-09-12 | — | — | CN | disclosed |
| US-11597235-B2 | Methods relating to polyurethane foam-containing and degradable foam-containing tires, and degradable foam-containing tires | BRIDGESTONE AMERICAS TIRE OPERATIONS, LLC (US) | 2023-03-07 | — | — | US | disclosed |
| WO-2022152748-A1 | MEMBRANE FOR WATER FILTRATION | AQUAPORIN A/S (DK) | 2022-07-21 | — | — | WO | disclosed |
| US-11267797-B2 | Anticancer agent | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2022-03-08 | — | — | US | disclosed |
| CN-113773424-A | Catalyst component for olefin polymerization and application | 中国石油化工股份有限公司 | 2021-12-10 | — | — | CN | disclosed |
| WO-1999066009-A2 | FUEL COMPOSITIONS EMPLOYING CATALYST COMBUSTION STRUCTURE | ORR WILLIAM C (US) | 1999-12-23 | — | — | WO | disclosed |
| EP-0537426-B1 | A germicidal and fungicidal agent and a germicidal and fungicidal method | NICCA CHEMICAL CO (JP) | 1995-12-27 | — | — | EP | disclosed |
| US-5391564-A | E.g., rhizoxin-13-yl 3-methylthiopropionate; anticarcinogenic agents | SANKYO COMPANY, LIMITED (JP) | 1995-02-21 | — | — | US | disclosed |
| US-5362910-A | Germicidal and fungicidal agent and a germicidal and fungicidal method | NICCA CHEMICAL CO., LTD. (JP) | 1994-11-08 | — | — | US | disclosed |
| US-5352689-A | Rhizoxin derivatives and their use as anti-tumor agents | SANKYO COMPANY, LIMITED (JP) | 1994-10-04 | — | — | US | disclosed |
| EP-0350315-B1 | RHIZOXIN DERIVATES AND THEIR USE AS ANTI-TUMOR AGENTS | SANKYO COMPANY LIMITED (JP) | 1993-06-16 | — | — | EP | disclosed |
| EP-0537426-A1 | A germicidal and fungicidal agent and a germicidal and fungicidal method | NICCA CHEMICAL CO., LTD. (JP) | 1993-04-21 | — | — | EP | disclosed |
| EP-0350315-A1 | Rhizoxin derivates and their use as anti-tumor agents | SANKYO COMPANY LIMITED (JP) | 1990-01-10 | — | — | EP | disclosed |
| US-4677173-A | Process for the production of suspension polymerizates | DEGUSSA AG (DE) | 1987-06-30 | — | — | US | disclosed |
| US-4352899-A | EPOXY RESIN, ORGANIC PHOSPHORUS COMPOUND, ZINC POWDER, MAGNESIUM COMPOUND | SAKAI CHEMICAL INDUSTRY CO., LTD. (JP) | 1982-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11267797-B2 | Anticancer agent | TP53, NTPCR, NQO1 | LAP3 753/4885MMP1 2080/4885MMP2 1456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.